Compared with placebo, secukinumab demonstrated superior pain reduction in moderate to severe hidradenitis suppurativa in two phase 3 trials. Improvements in pain were sustained through week 52 and ...

This article reports a clinically significant case of secukinumab exposure during pregnancy in a patient with severe plaque psoriasis and reviews current evidence regarding the safety of biologic ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...